For the quarter ended June 2025, 10x Genomics (TXG) reported revenue of $172.91 million, up 12.9% over the same period last year. EPS came in at $0.28, compared to -$0.32 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $139.44 million, representing a surprise of +24%. The company delivered an EPS surprise of +180%, with the consensus EPS estimate being -$0.35.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

10x Genomics (TXG) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +180.00%. A quarter ago, it was expected that this life science technology company would post a loss of $0.45 per share when it actually produced a loss of $0.36, delivering a surprise of +20%.Over the last fou ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact name of re ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $173 million, up 13% year-over-year, but excluding the settlement revenue, it was $146 million, down 5% [21][5] - Total consumables revenue was $122.2 million, down 1%, with Chromium consumables revenue at $85.8 million, down 9% [22][21] - Gross profit for Q2 was $125.1 million, with a gross margin increase to 72% from 68% year-over-year, primarily due to higher license and royalty revenue [26][21] - Net income for the period was $34.5 million compared to a net loss of $37.9 million in the previous year [27][21] Business Line Data and Key Metrics Changes - Spatial consumables revenue was $36.4 million, up 24%, driven by Xenium consumables revenue [22] - Total instrument revenue was $14.5 million, down 39%, with Chromium instrument revenue at $5.7 million, down 35% [23][22] - Services revenue increased by 47% to $8.5 million, primarily due to an increase in Xenium service plans [24][22] Market Data and Key Metrics Changes - Americas revenue was $78.9 million, down 15% year-over-year, while EMEA revenue was $34.7 million, down 7% [24] - APAC revenue was $32 million, up 41% year-over-year, benefiting from a temporary pull forward in purchasing activity in China [25][24] Company Strategy and Development Direction - The company is focused on advancing technology leadership in single cell and spatial biology, with new product launches aimed at lowering costs and expanding applications [12][19] - The acquisition of Scale Biosciences is expected to enhance the Chromium platform and broaden access to single cell analysis [19][28] - The company aims to maintain operational efficiency while investing in long-term growth despite a challenging funding environment [18][29] Management's Comments on Operating Environment and Future Outlook - The current funding environment is challenging, particularly in academic research, with cautious customer spending and extended project timelines [6][11] - Management noted that while there are signs of optimism among customers, actual spending remains conservative due to slow disbursement of funds [37][38] - The company expects Q3 revenue to be in the range of $140 million to $144 million, reflecting cautious customer spending behavior [28][21] Other Important Information - The company ended the quarter with $447 million in cash, cash equivalents, and marketable securities [27] - The company is committed to cost management and cash generation while pursuing strategic priorities [18][29] Q&A Session Summary Question: Can you discuss the current academic research funding environment? - Management noted that while there is more optimism compared to previous months, spending remains cautious due to slow fund disbursement and uncertainty around budgets [37][38] Question: What is the strategic rationale behind the Scale acquisition? - The acquisition aims to lower costs and drive higher scale in single cell applications, enhancing the company's existing product capabilities [41][42] Question: How is the sales force for Xenium performing in Europe? - The sales team is fully in place and ramping up, with improved execution despite a challenging capital expenditure environment [56][59] Question: What are the expectations for revenue from the Scale acquisition? - Near-term revenue impact from the acquisition is expected to be minimal, with a focus on integrating technologies into the broader portfolio [49][48] Question: What factors could unlock customer spending in the future? - Budget clarity for the next year and the actual disbursement of funds are seen as critical factors for unlocking customer spending [85][86]

Exhibit 99.1 10x Genomics Reports Second Quarter 2025 Financial Results PLEASANTON, Calif. August 7, 2025 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025. Recent Updates "The second quarter unfolded largely as anticipated," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "Amid continued uncertainty in the funding environment, we're encouraged by the resilience of our business and the dedicati ...

Torex Gold Reports Q2 2025 ResultsSolid operational momentum through the end of the quarter sets the Company up for a strong second half of the yearAugust 06, 2025 6:00 PM EDT | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - August 6, 2025) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three and six months ended June 30, 2025. ...

10x Genomics (TXG) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a changing e ...

Transaction Overview - Torex Gold is set to acquire all outstanding shares of Prime Mining, implying an equity value of $449 million (US$327 million)[19] - The transaction consideration is an exchange ratio of 0.0600 Torex common shares per Prime Mining share, representing an offer price of $2.57 per Prime Mining share based on Torex's closing price on July 25, 2025[19] - This represents a 32.4% premium based on the 30-day volume-weighted average prices of Torex and Prime Mining and an 18.5% premium based on spot prices[19] Benefits to Torex Gold Shareholders - The acquisition diversifies Torex's asset base by adding the Los Reyes project, a high-quality advanced exploration/development asset, to drive growth[20] - The Los Reyes project boasts a sizeable mineral resource, materially increasing Torex's resource base[20] Benefits to Prime Mining Shareholders - Prime Mining shareholders receive an immediate and significant premium, including a 32.4% premium to the 30-day VWAP and an 18.5% premium to spot prices[21] - Prime Mining shareholders gain participation in a high-margin, growing gold-copper company through a 10.7% ownership in the pro forma company[21] Los Reyes Project Highlights - The Los Reyes project has a multi-million ounce deposit, including a high-grade mill resource[29] - The Los Reyes project contains total indicated resources of 49.0 million tonnes with a gold grade of 0.95 g/t and a silver grade of 34.2 g/t, containing 1,491 koz of gold and 54.0 Moz of silver[30] - The Los Reyes project contains total inferred resources of 17.2 million tonnes with a gold grade of 0.97 g/t and a silver grade of 39.0 g/t, containing 538 koz of gold and 21.6 Moz of silver[30] Exploration and Development - Torex has budgeted $45 million towards drilling in 2025 (124,500 metres) across its properties[41]

Core Insights - 10x Genomics and A*STAR Genome Institute of Singapore have launched a collaboration for the TISHUMAP project aimed at drug target discovery and precision medicine for cancer and inflammatory diseases [1][2][3] Group 1: Project Overview - The TISHUMAP project will analyze up to 2,500 formalin-fixed paraffin-embedded (FFPE) clinical tissue samples from various cancers, including gastric, liver, and colorectal cancers [2] - The project utilizes 10x Genomics' Xenium platform, which allows for visualization of gene activity within individual cells in intact tissues, providing a detailed molecular-level map of cellular interactions [2][4] - The collaboration aims to develop new diagnostics and personalized treatment plans by identifying novel biomarkers and drug targets through advanced AI analysis [2][3] Group 2: Collaboration Details - A*STAR GIS and 10x Genomics will work on both data generation and analysis, creating tailored gene panels and intelligent software pipelines for managing large datasets [3] - The partnership focuses on streamlining lab workflows and developing advanced tools for sample preparation, imaging, and spatial biology data analysis [3] Group 3: Company Background - 10x Genomics is a life science technology company that provides integrated research solutions for single cell and spatial biology, contributing to breakthroughs in various fields including oncology and immunology [5] - A*STAR GIS is part of Singapore's Agency for Science, Technology and Research, focusing on genomic sciences to improve human health and societal impact [6][7]

Core Insights - Torex Gold Resources Inc. reports excellent drilling results from the northern extension of the EPO deposit, indicating strong potential for resource expansion and enhanced production profiles beyond 2035 [1][4][31] Drilling Results - The recent drilling program has yielded high-grade intercepts, including 55.18 grams per tonne (gpt) AuEq over 20.1 meters in drill hole ML24-1049DA, and 4.92 gpt AuEq over 35.7 meters in ML24-1042 [3][7] - The northern portion of EPO mineralization extends over an area of at least 500 x 200 meters with vertical continuity exceeding 100 meters [3][12] Resource Expansion - The 2024 drilling program successfully added approximately 233,000 gold equivalent ounces (oz AuEq) to Inferred Resources, primarily from the northern area of the deposit [2][7] - The ongoing drilling aims to upgrade Inferred Resources to Indicated Resources, with expectations for a significant increase in resources by the year-end 2025 mineral reserve and resource update [9][16] Production Outlook - Torex is on track to achieve first production from EPO by the end of 2026, with a projected minimum annual production of at least 450,000 oz AuEq through 2030 [4][31] - The company has budgeted approximately $10 million for drilling at EPO, with $5 million allocated specifically for the northern extension [17][32] Geological Context - The EPO deposit is characterized by a complex geological setting, including the Morelos Formation and various intrusive phases, which contribute to the mineralization [18][19] - The mineralization is controlled by structural features such as the La Avispa fault, which influences the distribution of mineralized zones [11][19]